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Abstract 
Layered gadolinium hydroxides (LGdH) have significant potential in simultaneous drug delivery and 
magnetic resonance imaging (MRI). In this work, we synthesized LGdH nanocomposites surface 
functionalised with SiO2 nanodots (LGdH@SiO2). We find these to have good dispersibility in cell 
culture medium, and a reduced tendency to aggregate compared to their uncoated analogue. 
Under the optimal reaction conditions, SiO2 nanodots were evenly spread across the surface of the 
LGdH particles. We further intercalated ibuprofen (Ibu) and 5-fluorouracil (5FU) into LGdH@SiO2, 
and explored the use of the resultant composites for drug delivery in vitro. While the SiO2 coating 
could effectively reduce aggregation of the Ibu intercalate prepared by ion exchange from the 
parent LGdH, it was noted to increase aggregation in the case of the 5FU-loaded systems produced 
by coprecipitation. With a SiO2 coating, 5FU release from the composite was almost zero-order at 
pH 7.4. The LGdH-5FU@SiO2 composites can effectively inhibit the growth of A549 cells (a 
human adenocarcinoma cell line). In contrast, the Ibu-loaded materials are highly biocompatible. 
After SiO2 modification, LGdH-5FU@SiO2 retains the same proton relaxivity properties as LGdH-
5FU, while LGdH-Ibu@SiO2 becomes suitable for use as a negative contrast agent in MRI. Overall, 
we find the LGdH@SiO2 nanocomposites are promising materials for theranostic applications. 
1. Introduction
Layered materials have been widely employed in drug delivery.1-3 Given that many APIs have
carboxylic acid groups and can form anions, anion-exchanging layered systems have significant
promise here. The latter are made up of positively charged layers held together by covalent
bonding; anions are located between adjacent layers to ensure charge balance, and thereby a
three-dimensional lamellar structure is constructed.4 Such anion-exchangeable layered materials
not only have a rich interlayer chemistry, but can also be exfoliated into single layers.
Layered double hydroxides (LDHs) comprise the most frequently studied family of anion-
exchangeable layered materials5 and have been explored in diverse fields, for instance as flame 
retardants,6,7 catalysts and catalyst precursors,8 CO2 adsorbents,9-13 cement additives,14 and drug 
delivery systems.15-18 Many LDHs have good biocompatibility and can provide pH sensitive payload 
release as well as protecting the anions in their interlayer regions.19-22 Their potency in drug 
delivery has been demonstrated in a number of studies.23,24 In addition, an increasing number of 
investigations into hierarchical LDH-drug nanocomposites with controllable morphology have been 
reported. For instance, Zhao et al. developed a method to obtain LDH@mesoporous silica core-
shell nanomaterials with great potential for drug delivery and hyperthermia therapy.25 In other 
work, Duan et al. designed three-component microspheres with a SiO2-coated Fe3O4 core and a 
LDH shell, and showed that such materials can be used to purify recombinant proteins, as well as 
in drug delivery and as biosensors.26  
Beyond LDHs, there are alternative anion-exchangeable layered hydroxides that have been 
employed in drug delivery, albeit to a lesser extent. Layered rare earth hydroxides (LRHs) are one 
such group of such materials. The anion exchangeable class of LRHs can be defined as 
[R2(OH)5]+(An-)1/n·yH2O (where R represents lanthanide cations, An- is an anion, and 1 ≤ y ≤ 2), and 
includes materials such as [Gd2(OH)5]Cl·1.5H2O and [Yb2(OH)5]Cl·1.5H2O. The inorganic anions in 
the interlayer region of LRHs can be replaced by alternative inorganic or bioactive organic 
molecules.27,28 Moreover, the presence of rare-earth ions in the layers gives LRHs magnetic and 
fluorescent features which cannot easily be obtained with LDHs. The twin benefits of anion-
exchange and magnetic/fluorescent functionality give LRHs great potential for medical 
technologies.29,30 For instance, layered gadolinium hydroxides (LGdHs) can be applied in magnetic 
resonance imaging (MRI).29 Xu et al. recently undertook a detailed investigation into the drug 
delivery and MRI performance of LGdH intercalates.31 They intercalated diclofenac, ibuprofen and 
naproxen into LGdH and found that the resultant LGdH-drug nanohybrids are promising materials 
for theranostic applications.  
One major challenge to clinical translation arises from the fact the LRH and LDH nanoparticles 
can easily agglomerate in cell culture medium and in vivo, resulting in a smaller amount of 
nanosized particles that can be internalized by cells and thus reducing drug delivery efficiency.32 As 
a result of this aggregation, the nanocomposites often have low bioavailabilty and short circulation 
times in vivo. To prevent such aggregation, surface functionalization can be used.26,33-35 However, 
although a number of reports confirm the utility of LGdHs for MRI and/or drug delivery,30,31 to date 
there are no reports into the surface functionalization of LGdHs. This is a vital step which must be 
addressed for these materials to be translated towards clinical applications. 
In this work, we explore for the first time the surface functionalization of LGdH systems. To do 
this we employ a silica-based coating, which has previously been found to be potent for LDH 
systems,35 and report the synthesis of SiO2 nanodot coated LGdH nanohybrids (LGdH@SiO2). The 
cellular uptake of LGdH@SiO2 was explored, before two model drugs (5-fluorouracil (5FU) and 
ibuprofen) were intercalated into the LGdH and LGdH@SiO2 materials. These nanocomposites 
were fully characterized and their drug release profiles, biocompatibility and potential for magnetic 
resonance imaging studied in detail. 
 
2. Experimental  
2.1 Materials 
Chemicals were purchased as follows: gadolinium chloride hexahydrate (Alfa Aesar, 99%), sodium 
hydroxide (Fisher Scientific), sodium chloride (Sigma-Aldrich), n-octane (Alfa Aesar, >98%), L-
arginine (Sigma-Aldrich, >98%), tetraethoxysilane (Alfa Aesar, 98%), Arsenazo III (Sigma-Aldrich), 5-
fluorouracil (5FU; Fisher Scientific, 99%) and ibuprofen sodium salt (Ibu, Santa Cruz 
Biotechnology, >98%). All materials were used without further purification. 
 
 
2.2 Synthesis  
Preparation of LGdH and LGdH-5FU: The LGdH precursor was obtained using a hydrothermal 
method as previously reported.31 First, GdCl3·6H2O (2.23 g, 6 mmol) was dissolved in deionized 
water (15 mL) . It was then added dropwise to a second solution containing NaCl (0.41 g, 7 mmol) 
and NaOH (0.42 g, 10.5 mmol) in deionized water (5 mL). After stirring for 10 min, the resultant 
suspension was transferred to a 23 mL Telfon-lined stainless steel autoclave and treated at 150 °C 
for 15 h. Solid products were collected by filtration, washed with deionized water and ethanol, and 
dried at 40 °C for 24 h. 5FU was intercalated into LGdH via co-precipitation. In brief, an aqueous 
solution (6 mL) of NaOH (0.2 g, 5 mmol) solution was added to a 0.4 M GdCl3·6H2O solution (7.5 
mL) with stirring for 10 min. The slurry produced was separated after centrifugation and re-
suspended in a solution (15 mL) containing 5FU (0.455 g, 3.5 mmol, pH=8-9, neutralized by 1 M 
NaOH solution). After stirring for 1 h at room temperature, the solid product was washed with 
deionized water and ethanol and then re-suspended in deionized water (20 mL). This suspension 
was transferred to a 23 mL Telfon-lined stainless steel autoclave and heated at 90 °C for 15 h. 
Preparation of LGdH@SiO2 and LGdH-5FU@SiO2 nanocomposites: SiO2 nanodots were coated on 
LGdH and LGdH-5FU following a previously reported procedure.36 First, 0.42 mL of TEOS and 1.04 
mL of octane were added to a deionized water solution of L-arginine (1 mg mL-1, 14 mL). The 
mixture was stirred for 4 h at 60 °C.37 A suspension of 56 mg of LGdH or LGdH-5FU in deionized 
water (14 mL) was then added into the above solution, and the reaction stirred at 60 °C for 20 h. 
The final nanocomposites were dried at 40 °C overnight after washing with deionized water and 
ethanol.  
Preparation of LGdH-Ibu and LGdH-Ibu@SiO2: LGdH-Ibu and LGdH-Ibu@SiO2 were synthesized via 
an ion-exchange method using LGdH and LGdH@SiO2 as precursors. 150 mg of the precursor 
material was dispersed in an aqueous solution (15 mL) containing ibuprofen sodium (222 mg, 0.1 
mmol). After constant stirring at 60 °C for 24 h, the resultant materials were filtered, washed with 
deionized water and ethanol, and then dried in an oven at 40 °C overnight.  
Preparation of LGdH-FITC and LGdH-FITC@SiO2: Fluorescently-labelled systems were obtained by 
mixing a suspension of LGdH or LGdH@SiO2 (6 mg mL-1, 10 mL, in water) with an aqueous 
fluorescein isothiocyanate isomer I (FITC) solution (pH=10.0, 6 mg mL-1, 10 mL). The mixtures were 
stirred at room temperature for 12 h, and the solid product isolated by filtration and washed 
repeatedly with water until the filtrate was colourless. 
 
2.3 Characterization 
X-ray diffraction: X-ray diffraction (XRD) data were collected in reflection mode on a Rigaku 
MiniFlex 600 diffractometer over the 2θ range from 3 to 45°, using Cu Kα radiation (λ = 1.5418 Å). 
Infrared spectroscopy A Spectrum 100 spectrometer (PerkinElmer) fitted with an attenuated total 
reflectance attachment was employed to obtain spectra over the range 650 to 4000 cm-1.  
Elemental analysis: The content of Gd in the materials was analyzed using an ISA Jobin Yvon Ultima 
2C inductively coupled plasma-optical emission (ICP-OES) simultaneous/sequential spectrometer 
running at 1 kW power with a 40.68 MHz radiofrequency Argon plasma. The plasma gas flow was 
14 L min-1. The nebuliser pressure was 2.6 bar at a 1 mL min-1 sample flow rate. Spectral lines for 
gadolinium were measured at 326.224 nm. Samples were digested for ICP-OES using hot nitric acid. 
Transmission electron microscopy (TEM) images were obtained on a CM 120 Bio-Twin instrument 
(Philips). For this, samples were first dispersed in ethanol, dropped onto carbon-coated TEM grids 
(TAAB), and then allowed to dry. 
Dynamic light scattering (DLS) was undertaken to obtain the particle size distribution and zeta 
potential of the nanomaterials. 2 mg of sample was dispersed into 2 mL of water or 2 mL of a 10 
mM NaCl solution for size and zeta potential measurements respectively. After ultrasonication for 
20 min, data were collected on a Zetasizer NanoZS instrument (Malvern Instruments). Similar 
measurements were made where the nanocomposites were dispersed in DMEM medium with 10 % 
v/v FBS.  
Stability assays were conducted under both acidic and neutral conditions. First, 0.2 mg of Arsenazo 
III was dissolved in 20 mL of HCl (pH 1.5) or phosphate buffered saline (PBS, pH 7.4). 20 mg of each 
of the LGdH materials was dispersed in the Arsenazo III solutions, and the mixture stirred at 37 °C 
for 2 h in acidic solution or 24 h in PBS. The suspension was then filtered through a PVDF-type 
syringe filter (0.22 μm) before a Cary 100 UV-visible spectrophotometer (Agilent Technologies) was 
employed to analyze the concentration of Gd3+ at 652 nm. For comparison, positive (GdCl3·6H2O) 
and negative controls (HCl or PBS) were established. 
Drug release studies: PBS solutions at pH 5.0 and pH 7.4 were used as the release media. 30 mg of 
each sample was dispersed in 200 mL of the release medium under constant stirring at 100 rpm. 
The temperature was maintained at 37 ± 0.5 °C. At given time intervals, 5 mL of the solution was 
removed for analysis, and an equal volume of fresh pre-heated medium added to ensure a constant 
volume. The aliquots were filtered through a 0.22 μm filter and the drug concentration determined 
using a UV-vis spectrophotometer (7315, Jenway).  
Cell culture: A549 cells, a adenocarcinomic human alveolar basal epithelial cell line, were used for 
in vitro studies. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) 
supplemented with pre-heated fetal bovine serum (10% v/v), L-glutamine (1% v/v) and penicillin 
(1% v/v) in a humidified atmosphere (37 °C, 5% CO2). For viability assays, A549 cells were pre-
grown in 96 well plates. 1 × 104 cells in 180 μL of medium were seeded into each well and cultured 
for 24 h. The medium was aspirated and 180 μL of DMEM containing various concentrations of 
LGdH-drug and LGdH-drug@SiO2 nanocomposites was added. After a further 24 h incubation, the 
CellTiter-GloTM assay was employed to investigate cell viability. The wells were aspirated, followed 
by addition of 100 μL of the fluorescent reagent and 100 μL of fresh medium to each well. The 
plate was then left for 10 min at room temperature. A SpectraMax M2e spectrophotometer was 
utilized to record luminescence data. The cell viability of the cells was determined using the 
following equation: 
Viability = 100 ×
(𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑡𝑜 𝐿𝐺𝑑𝐻 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
(𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
 
Three independent experiments were carried out, with three replicates per experiment. Data 
are reported as mean ± S.D.  
Proton relaxivity: Samples were dispersed in an aqueous 1% w/v xanthan gum solution to obtain 
suspensions at various Gd3+ concentrations. These were added into NMR tubes of 10 mm diameter, 
and homogeneous dispersions obtained after ultrasonication and microwave treatment. A 
Minispec mq20 relaxometer (23 MHz, 0.47T) was used to record both the longitudinal (T1) and 
transverse (T2) relaxation times at 37 °C. For the measurement of T1, the standard inversion-
recovery method was employed with a typical 90o pulse calibration of 250 µs with 4 scans per 
experiment; for T2, the Carr-Purcell-Meiboom-Gill (CPMG) method was used with 4 scans per 
experiment. A minimum of 3 different concentrations of stable nanoparticle samples were 
prepared and relaxation time measured for each sample. r1 and r2 relaxivity values were calculated 
from curves plotted of R1 (1/T1, s-1) or R2 (1/T2, s-1) vs. [Gd] concentration (mM) and analysis of the 




3. Results and discussion  
3.1 Synthesis and characterisation of LGdH and LGdH@SiO2 
LGdH was synthesized following a previously reported protocol.31 TEM showed the LGdH 
nanoparticles to have plate-like morphologies and sizes of ca. 200 nm in width and 400 nm in 
length (Fig. 1a). DLS measurements concur with these values, giving a mean hydrodynamic 
diameter of 400 ± 10 nm (PDI 0.457). After mixing the LGdH-Cl material with tetraethoxysilane at 
a 1:1 mass ratio, the presence of spherical nanoparticles around 10-20 nm in size can be seen on 
the LGdH-Cl surface, indicating successful SiO2 formation (Fig. 1b). Following purification, no free 
SiO2 particles were evident on any of the grids examined, thus confirming that the SiO2 is indeed 
surface grafted. After SiO2 coating, the zeta potential of all the nanocomposites changed from 
+56.8 ± 2.5 mV for LGdH to -33.1 ± 1.1 mV, consistent with the successful modification of particle 
surfaces with negatively charged SiO2 nanodots.35,38 The DLS data reveal that the LGdH@SiO2 
particles have slightly smaller hydrodynamic diameters than the precursor, with Z-average particle 
sizes reduced (from 400 ± 10 nm) to 350 ± 8 nm (PDI 0.314). The reduction in PDI is consistent with 
reduced aggregation. 
The XRD pattern of the LGdH precursor (Fig. 1c) matches well with the reported pattern39 and 
the strong (0l0) basal lines indicate the successful formation of a layered structure. The IR spectrum 
(Fig. 1d) contains characteristic absorption peaks in the range from 3646 to 3383 cm-1 
corresponding to the hydroxyl stretching vibrations, and a band at 1667 cm-1 which can be ascribed 
to the δ-bend of water.31 Other bands between 1600 and 1400 cm-1 result from the inclusion of 
small amounts of carbonate in the system. Elemental microanalysis data indicate the chemical 
formula of the LGdH material to be [Gd2(OH)5]Cl0.8(CO3)0.1·H2O (% obsd. [calcd.]: C 0.33 [0.26]; N 0 
[0]; H 1.64 [1.56]). All these observations are in line with the literature31, confirming the successful 




Fig. 1 Data demonstrating the successful synthesis of LGdH and LGdH@SiO2. TEM images of (a) LGdH and (b) 
LGdH@SiO2; (c) XRD patterns; (d) IR spectra. 
 
XRD and IR data for the LGdH@SiO2 system are given in Fig. 1c, d. The characteristic Bragg 
reflections of LGdH are retained in the XRD pattern after SiO2 modification (Fig. 1c), and no changes 
except a slight broadening of the reflections (likely owing to the induction of some stacking defects) 
can be seen with LGdH@SiO2. The growth of SiO2 nanodots on the LGdH particle surface is further 
demonstrated in the FTIR spectra (Fig. 1d). In addition to the –OH and H2O bands of LGdH, the 
LGdH@SiO2 nanohybrids also exhibit two strong peaks at 1105 and 780 cm-1, which can be 
attributed to Si-O-Si and O-Si-O stretching vibrations.40 Hence, the LGdH precursor has been 
successfully functionalized with SiO2 nanodots. When the size of the LGdH and LGdH@SiO2 systems 
was studied in water and culture medium to explore the effect of protein absorption (which is 
inevitable in vivo) on particle behavior, the naked LGdH particles were observed to aggregate 
markedly, while the LGdH@SiO2 particles appear stable (ESI, Fig. S1). The dispersibility and colloidal 
stability of LGdH in culture medium is thus improved after coating with SiO2 nanodots.41  
 
3.2 Drug intercalated LGdH and LGdH-drug@SiO2 nanocomposites 
We next explored the potential of using the LGdH@SiO2 nanocomposite as a carrier to load Ibu 
(an anti-inflammatory drug) and 5FU (an anticancer drug). LGdH-Ibu and LGdH-Ibu@SiO2 were 
prepared using ion exchange with pre-formed LGdH and LGdH@SiO2. The reflections in XRD are 
broader and lower intensity after intercalation of Ibu, owing to the introduction of stacking defects, 
as has been noted many times in the literature.36,41 The characteristic reflections of LGdH-Ibu are 
also present in the LGdH-Ibu@SiO2 system: both show a 010 reflection with the d-spacing of 23.58 
Å. The interlayer spacing for the Ibu intercalate is close to that has been reported before (23.46 
Å),31 and the XRD pattern for LGdH-Ibu (Fig. 2a) matches well with that from previous work.31  
Successful intercalation of Ibu is further confirmed by IR spectroscopy (Fig. 2b). The broad peak 
at around 3500 cm-1 can be ascribed to the OH stretching vibration of the hydroxide layers. In 
addition, peaks distinctive of Ibu at 1543 and 1400 cm-1 (asymmetric and symmetric stretching 
vibrations of the -COO- group)42,43 can be seen, verifying successful drug loading.31 Further, the 
two strong peaks at 2869 and 2955 cm-1 are typical of alkyl stretching vibrations.44 The LGdH-
drug@SiO2 nanohybrid additionally displays a clear band at around 1105 cm-1, confirming the 
coating with SiO2. After the addition SiO2, the intensity of the absorption bands at ca. 3500 and 
1800 – 1400 cm-1 are notably weaker, due to the presence of surface SiO2. 
 
 
Fig. 2. (a) XRD patterns and (b) FTIR spectra for the LGdH-drug, and LGdH-drug@SiO2 nanocomposites. 
 
LGdH-5FU nanohybrids were synthesized for the first time in this work. The XRD data (Fig. 2a) 
show a broad 010 reflection at 10.39 Å for LGdH-5FU and at 10.86 Å for LGdH-5FU@SiO2, an 
increase in d-spacing from the 8.41 Å of LGdH-Cl. This suggests intercalation of the drug, but the 
broadness of the reflections indicates materials with considerable structural disorder and makes it 
hard to confirm successful drug loading by XRD. To determine whether 5FU was intercalated or 
whether a physical mixture of the two had formed, the XRD pattern of a physical mixture of 5FU 
and LGdH was collected (Fig. 2a). The two patterns have distinct differences. The latter matches 
very closely the pattern of pure LGdH, indicating no intercalation. The stark differences between 
this and the pattern after coprecipitation suggests successful intercalation was achieved, since 
after co-precipitation the basal reflections of the parent LGdH are no longer visible. Further, the IR 
spectra of the physical mixture is similar to that of the LGdH precursor, while there are a range of 
additional peaks characteristic of 5FU in LGdH-5FU and LGdH-5FU@SiO2. As shown in Fig. S2, these 
arise at 1682 and 1620 cm-1 (C=O and C=C stretches), 1580-1300 and 817 cm-1 (ring stretching 
modes),45 and 1210 cm-1 (C-F vibrations).45 The IR results further confirmed the successful loading 
of 5FU into LGdH. As for the Ibu analogues, the drug and LGdH absorbance bands become weaker 
after functionalization with SiO2. 
CHN microanalysis was used to determine the elemental compositions of the drug intercalates 
(Table 1). The zeta potentials were additionally quantified (Table 1). The zeta potential of LGdH was 
+56.8 ± 2.5 mV, which reduces somewhat after intercalation with Ibu and 5FU (to +41.3 ± 0.9 and 
+30.6 ± 1.4 mV, respectively), indicative that there is some drug present on the surface of the 
particles. The zeta potential is further reduced after SiO2 modification, to +6.4 ± 0.3 and -3.4 ± 5.8 
mV. The drug loadings of LGdH-Ibu and LGdH-5FU (calculated from the elemental analysis findings) 
are 32.5 and 20.6 % w/w, respectively. In the SiO2 coated systems, the loadings are 6.3 and 10.0 % 
w/w. The reduced loading in the case of LGdH-Ibu@SiO2 (cf. LGdH-Ibu) is presumably a result of 
the SiO2 nanospheres blocking entry to some of the interlayer edges, and thus impeding the ion 
exchange process. With the 5FU analogue, the reduction in loading after SiO2 functionalisation is 
less significant, but nevertheless distinct; it must be the case that some 5FU leaked from the 
composites during the surface modification step. 
Fig. 3 gives TEM images of the drug-loaded nanocomposites. It can be observed that there were 
fewer nanodots on the surfaces of the drug-loaded systems compared with the LGdH@SiO2 
precursor, but the coating is nevertheless visible. The particle size of LGdH-5FU (36 ± 11 nm) 
measured by TEM is notably smaller than that of LGdH-ibu (405 ± 65 nm). This can be ascribed to 
the different synthetic routes which had to be applied. While the LGdH-Ibu@SiO2 material appears 
to exist as isolated particles with large primary particles in TEM (Fig. 3a), the LGdH-5FU and LGdH-
5FU@SiO2 systems are more aggregated (Fig. 3b,c). These findings are borne out by the DLS data. 
We observe sizes of 673 ± 72 nm (PDI 0.41 ± 0.106) and 454 ± 16 nm (PDI 0.16 ± 0.04) for LGdH-
Ibu and LGdH-Ibu@SiO2 respectively, while for LGdH-5FU and LGdH-5FU@SiO2 the equivalent 
values are 160 ± 5 nm (PDI 0.41 ± 0.04) and 1074 ± 69 nm (PDI 0.3 ± 0.03). It is thus clear that for 
the Ibu-loaded materials the SiO2 coating causes a reduction in aggregation, as was noted for the 
parent LGdH. However, for the 5FU-loaded formulations the opposite trend is noted. This can 
presumably be attributed to the synthesis method: the Ibu was intercalated by ion exchange into 
the preformed LGdH layers, while 5FU-loaded systems had to be prepared by coprecipitation, 
resulting in notably smaller primary particle sizes. The increase in aggregation observed with LGdH-
5FU@SiO2 by DLS is also consistent with the zeta potential value of this material: the zeta potential 
is close to zero, which will encourage flocculation. 
 
Table 1 The physicochemical properties of the LGdH-drug and LGdH-drug@SiO2 nanocomposites. The zeta potential 
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 [Gd2(OH)5](C4H2FN2O2)0.85Cl0.15·H2O 20.6 







 [Gd2(OH)5](C4H2FN2O2)0.47Cl0.53·H2O@1.8SiO2 10.0  















Fig. 3 TEM images of (a) LGdH-Ibu@SiO2; (b) LGdH-5FU; and (c) LGdH-5FU@SiO2. 
 
3.3 Nanocomposite stability 
Although Gd-based contrast agents are very powerful, and widely employed in the clinic, free 
Gd3+ is toxic to humans.46 We thus employed the Arsenazo(III) assay to evaluate the stability of the 
nanocomposites at pH 1.5 (mimicking the stomach) and pH 7.4 (representing the general 
physiological environment).47 Experiments were performed for 2 h and 24 h respectively, since 
these are approximately the amount of time that the composites would spend in the stomach and 
lower intestinal tract in vivo following oral application. Arsenazo(III) coordinates with Gd3+ to obtain 
a strongly-bound complex with a pH-dependent λmax.48 It has been reported that the λmax of the 
complex is 650 nm when the pH lies in the range of 3-4 or 6.4-8.49-51 The results of assays in which 
the nanoparticles were incubated in different pH solutions are presented in Fig. 7. 
In both acidic and neutral solutions, the positive control (GdCl3) displays a strong peak at 652 
nm, suggesting the formation of the Gd3+-Arsenazo complex. HCl or PBS alone has minimal 
absorbance at this wavelength. At pH 1.5, the LGdH, LGdH@SiO2, LGdH-drug and LGdH-drug@SiO2 
systems all show similar absorbance to the positive control at 652 nm, indicating that free Gd3+ has 
been released from the samples. Concentrations of 174 – 208 μg/mL are observed (see Fig. S3 for 
the calibration plot), indicating that 27.3% (LGdH), 19.2% (LGdH@SiO2), 29.5% (LGdH-Ibu), 23.1% 
(LGdH-Ibu@SiO2), 40.1% (LGdH-5FU) and 32.3% (LGdH-5FU@SiO2) of the Gd3+ had been released 
after 2 h. The Gd leaching is reduced after the introduction of SiO2. In contrast, at pH 7.4 the LGdH 
and LGdH-Ibu nanocomposites show only minimal absorbance at 652 nm, equating to 7.0 and 7.6% 
of the Gd content leaching, respectively. However, there is still significant absorbance visible for 
the 5FU systems at this pH, indicating a lack of stability. The Gd leaching is reduced after surface 
coating with SiO2 for 5FU (from 15.1% to 9.2%). 
 
 
Fig. 4 Assays of the stability of the various nanocomposites at (a) pH 1.5 for 2 h, and (b) pH 7.4 for 24 h, employing 
the Arsenazo(III) method.  
 
3.4 Drug release  
Drug release from the LGdH-drug and LGdH-drug@SiO2 composites were explored at pH 5 and 
pH 7.4. The pH 5 release medium was selected to mimic a late endosomal/lysosomal environment, 
while the pH 7.4 solution represents normal physiological conditions. The former was chosen 
because it is generally believed that the cellular uptake of small particles (< 200-300 nm) involves 
endocytosis in most cases, while larger particles were found to be taken up by phagocytosis.52-55 
Drug release data are given in Fig. 5. A burst of release is seen in most cases, which presumably 
can be attributed to the drug at the particle surface. LGdH-5FU exhibits similar drug release rates 
at both pH 5 and pH 7.4. LGdH-5FU@SiO2 displays a reduced final release percentage (around 45% 
at both pH 7.4 and pH 5) than LGdH-5FU after 48 h, which is likely due to the surface coating 
providing a steric barrier to drug release. At pH 7.4, the LGdH-5FU@SiO2 system released the drug 
in a zero-order manner in the first 25 h, while it behaves more similarly to LGdH-5FU at pH 5.  
For LGdH-Ibu, the final release percentage reaches almost 100 % after 48 h, in all the media 
studied (Fig. 5). Ibu release from LGdH-Ibu reached 50 % after 180 min at pH 7.4, while it takes 
longer (about 670 min) to reach 50 % release at pH 5. Ibu is a pH-sensitive drug with lower solubility 
in acidic conditions, which is likely to be responsible for the difference in release rates.56 For the 
LGdH-Ibu@SiO2 system, the amount of drug released is notably less than that of LGdH-Ibu after 48 
h (41% at pH 7.4, 30% at pH 5). Moreover, this material releases more rapidly in the earlier stages 
of the experiment, arriving at a maximum value after 3-5 h. It also appears that after reaching this 
maximum there is a small decline in drug release, likely to be due to some drug adsorbing back 
onto the LGdH composite.  
The SiO2 coating reduces the amount of drug released for both Ibu and 5FU, thought to be 
because the SiO2 nanodots on the surface of the particles provide some steric hindrance to drug 
release. Greater release percentages are observed for LGdH-Ibu than LGdH-5FU at the end of the 
experiment, which is expected to be a result of the ionisation of the Ibu COOH group increasing its 
solubility at the pHs investigated (in contrast, 5FU will form a neutral molecule after release).57,58 
 
 
Fig. 5 Drug release for 5FU at (a) pH 7.4, (b) pH 5, and Ibu at (c) pH 7.4, (d) pH 5. Three independent experiments 
were performed, and data are shown as mean ± S.D.  
 
The Bhaskar (Eqn. 1) and Avarmi-Erofe’ev models (Eqn. 2) were utilized to fit the release data. 
  ln (1 −
𝑀𝑡
𝑀𝑖𝑛𝑓
) = 𝑘𝑡0.65                           (1)                         
ln(− ln(1 − 𝛼)) = 𝑛 ln 𝑘 + 𝑛 ln 𝑡                       (2) 
For eqn (1), Mt is the amount of drug released at time t, and Minf the total amount of drug loaded 
in the carrier. For eqn (2), α = Mt/ Minf, n is an exponent that provides information on the reaction 
mechanism, and k is a rate constant. 
Fits of the two models to the release data are shown in the ESI, Figs. S4 and S5. For LGdH-5FU, 
LGdH-5FU@SiO2 and LGdH-Ibu both models in general fit the data well in both pH environments, 
although the Bhaskar fits for LGdH-5FU@SiO2 at pH 7.4 and for LGdH-5FU at pH 7.4 and 5 are rather 
poor. For LGdH-Ibu@SiO2, the release data cannot be fitted satisfactorily with either model. The 
Bhaskar model assumes that diffusion of the drug ions and/or replacement anions through the 
particle limits the release rate, and thus for LGdH-Ibu this can be assumed to be the rate limiting 
step to release.59,60 The value of n in Avrami-Erofe’ev equation also provides some information on 
the reaction mechanism.61 The values of n for LGdH-5FU@SiO2 in the pH 7.4 and pH 5 solutions 
were 0.74 and 0.72, while those for LGdH-5FU were 0.37 and 0.38. All of these suggest diffusion 
control, indicating that diffusion of replacement ions through solution limits the rate. This is 
consistent with the poor Bhaskar fit for these systems.62 For LGdH-Ibu, the values of n were closer 
to 1.0, indicating a 2D nucleation-controlled process. This is in agreement with the much better 
Bhaskar fit for this material. However, it should be noted that there a range of potential 




3.5 Cell viability 
The cytotoxicity of the LGdH and LGdH@SiO2 nanohybrids to A549 cells after 24 h was explored 
at a range of concentrations (Fig. 6a). The cell viability is always more than 100% of the untreated 
cells control, indicating that the nanocomposites are biocompatible and do not induce cytotoxicity 
to A549 cells. 
 
 
Fig. 6. In vitro cytotoxicity data for (a) LGdH and LGdH@SiO2; (b) 5FU intercalates; and, (c) Ibu intercalates. The 
concentration values given for 5FU and Ibu are those which would arise if 100% of the intercalated drug was 
released from the composite.  
 
It is clear from the data in Fig. 6 that the 5FU formulations are toxic to the cells, while the Ibu 
materials in general are not. The LGdH-Ibu@SiO2 system does appear to be toxic at low 
concentrations, however. The reasons for this are not clear. In most cases, the SiO2-functionlised 
materials result in higher viability that those without the surface coating. 
 These results can be explained by considering a balance of drug release and cellular uptake. 
In the 5FU case, the extent of release at the 24 h timepoint is reduced after SiO2 coating (from 62.8% 
to 34.4% after SiO2 coating). Both nanocomposites display more effective inhibition of cancer cell 
growth than free 5FU when the concentration of 5FU is 4.28 μg/mL or below. When the 
concentration increased to 10.7 and 21.4 μg/mL, more cancer cells are killed by LGdH-5FU than 
free 5FU, while LGdH-5FU@SiO2 is less potent. All the materials loaded with Ibu exhibit high 
biocompatibility, and seem to encourage cell growth. This is consistent with a previous study in the 
literature using Caco-2 cells.31 
 
3.6 Magnetic resonance imaging (MRI) behaviour 
MRI contrast agents (CAs) are regularly used clinically to improve image resolution and aid in 
disease diagnosis.63 The use of Gd-based nanomaterials as so-called positive MRI CAs has been 
widely explored.64-66 Such materials boost signal contrast through decreasing indigenous water 
proton relaxation times through close molecular interactions, as described by Solomon, 
Bloembergen and Morgan equations.67,68 The efficacy of MRI contrast agents can be assessed 
through the measurement of proton relaxation rates. The relaxation rate of water protons with 
respect to the concentration of contrast agent (according to Equation 1) provides an agents’ 




                                 (3) 
Where R1,2,obs is the observed relaxation rate of the agent in aqueous suspension (where 
R1=1/T1 and T1 is the longitudinal relaxation time of water protons and R2=1/T2 and T2 is the 
transverse relaxation time of water protons), R1,2,sol is the relaxation rate of the unaltered 
solvent system (i.e. in the absence of contrast agent) and [CA] is the mM concentration of 
the contrast agent in suspension, in this case, the [Gd] as measured by ICP-OES. In order to 
assess the contrast agent behaviour of LGdH-drug and LGdH-drug@SiO2, proton relaxation was 
measured at 23 MHz and 37 oC. r1 relaxivity is dominated by an inner sphere mechanism (of water 
coordination and exchange with paramagnetic Gd species). Herein, LGdH composites may be 
expected to exhibit r1 relaxation enhancement, due to the presence of Gd2(OH)5+ within their 
structures, with nearby hydrogen bonded water facilitating coordinative water exchange. The 
parent LGdH materials exhibit an r1 relaxivity of 3.27 mM-1s-1 (Fig. 7), which is comparable with 
molecular Gd chelate species and lower than other nanostructured Gd-species in literature, which 
may imply that water exchange is slow within these compositions. The parent LGdH materials show 
a decrease in r1 relaxivity upon intercalation with drug moeities (r1=2.02 mM-1s-1 for LGdH-Ibu and 
r1=1.51 mM-1s-1 LGdH-5FU), which is likely due to decreased water coordination and exchange due 
to the presence of the drug species in the internal cavities of the composites. The difference in r1 
values between LGdH-Ibu and LGdH-5FU are due to the large differences in composite size, as 
previously described (in section 3.2). Upon modification with SiO2 nanodots, r1 values for both 
composites reduced further (r1=0.81 mM-1s-1 for LGdH-Ibu@SiO2 and r1=0.41 mM-1s-1 LGdH-
5FU@SiO2), with SiO2 reducing the ability for water to coordinate and exchange with internalised 
Gd species on the composites due to their external location blocking water access.  
r2 relaxivity is dominated by outer sphere mechanisms and results from diffusive water 
interaction with inhomogeneities in local magnetic field strengths generated by magnetic 
composites. Herein, r2 values are significantly higher than those observed for r1 (r2=27.26 mM-1s-1 
for LGdH). High r2 relaxivities have previously been reported for LGdH species69 and here, r2 
relaxivites follow a similar trend to that observed for r1. LGdH-5FU samples exhibited lower r2 
values (r2=1.94 mM-1s-1 for LGdH-5FU and r2=0.81 mM-1s-1 LGdH-5FU@SiO2), due to their smaller 
particle sizes. An exception is observed for LGdH-Ibu@SiO2 (9.78 mM-1s-1), whose r2 increased 
relative to LGdH-Ibu (4.36 mM-1s-1). This may be due to the presence of SiO2 trapping water 
molecules inside internal LGdH cavities; alongside Ibu, this could enhance r2 values due to close 
proximity with the Gd species providing enhanced second sphere effects.  
 
 
Fig. 7. Relaxivity data for the LGdH, LGdH-drug and LGdH-drug@SiO2 nanocomposites, displaying (a and b) r1 and 
(c and d) r2 plots; and corresponding relaxivity (unit: mM-1s-1). 
 
 
Fig. 8. The r2/r1 values for the nanocomposites. 
 
  In general, MRI CAs can be classified as ‘positive’ CAs (exhibiting areas of hyperintense signal) or 
‘negative’ CAs (exhibiting hypointense signal), depending on their r2/r1 ratio, with positive CAs 
possessing r2/r1 values of ~1, and negative CAs presenting values r2/r1 >>1. 70 Herein, r2/r1 values 
for LGdH, LGdH-Ibu, LGdH-Ibu@SiO2, LGdH-5FU and LGdH-5FU@SiO2 are 8.35, 2.16, 12.05, 1.29 
and 1.98, respectively (Fig. 8), indicating that the parent LGdH and Ibu loaded nanocomposites 
exhibit preferentially ‘negative’ contrast enhancement capabilities, due to their large particle sizes 
and intercalation with Ibu, which enhances outer sphere interactions. LGdH-5FU and LGdH-
5FU@SiO2 on the other hand, appear to show much lower overall relaxivity enhancements, and as 
such, the r2/r1 ratio as an assessment of class of contrast agent becomes unreliable.  
 
4. Conclusions 
In this work, SiO2 coated layered Gd hydroxide (LGdH) nanocomposites were generated and 
explored as potential theranostic agents. The SiO2 coating method was first optimised, after which 
particles with good dispersibility were obtained via a facile and reproducible method. SiO2 
nanodots were uniformly distributed across the surface of LGdH nanoparticles under the optimal 
synthetic conditions. The coating reduced the particle size and helped to reduce particle 
aggregation. Ibuprofen (Ibu) and 5-fluorouracil (5FU) were further intercalated into the LGdH and 
LGdH@SiO2 nanocomposites. While the SiO2 coating could effectively reduce aggregation of the 
Ibu intercalate generated by ion exchange from the parent LGdH, it was noted to increase 
aggregation in the case of the 5FU-loaded systems prepared by coprecipitation. The drug release 
profile is pH-sensitive in the case of the ibuprofen composites, and was profoundly affected by the 
SiO2 coating. In particular, LGdH-5FU@SiO2 showed zero-order release at pH 7.4, and is more toxic 
to cancerous cells that free 5FU at higher concentrations. In contrast, the ibuprofen analogue is 
highly biocompatible. LGdH nanocomposites demonstrated strong r2 relaxivity enhancement and 
LGdH-Ibu samples in particular demonstrated promise as negative contrast agents.  
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